Severe Drug-Induced Liver Injury from Combination EncorafenibBinimetinib
Joint Authors
Gravbrot, Nicholas
Sundararajan, Srinath
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-07
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma.
Though generally tolerated well, mild to moderate aminotransferase elevations are common.
However, significant liver injury has not been demonstrated in the literature.
Here, we report the first case of severe hepatic injury associated with encorafenib/binimetinib in a 58-year-old gentleman requiring admission and extensive workup.
He was successfully treated by withdrawing the combination therapy, and liver function returned to normal range.
American Psychological Association (APA)
Gravbrot, Nicholas& Sundararajan, Srinath. 2019. Severe Drug-Induced Liver Injury from Combination EncorafenibBinimetinib. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1141891
Modern Language Association (MLA)
Gravbrot, Nicholas& Sundararajan, Srinath. Severe Drug-Induced Liver Injury from Combination EncorafenibBinimetinib. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-4.
https://search.emarefa.net/detail/BIM-1141891
American Medical Association (AMA)
Gravbrot, Nicholas& Sundararajan, Srinath. Severe Drug-Induced Liver Injury from Combination EncorafenibBinimetinib. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1141891
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141891